Fibrosis Lessens After Metabolic Surgery
Conditions
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Non-Alcoholic Fatty Liver Disease · Metabolic Dysfunction-Associated Steatohepatitis (MASH) · Liver Fibrosis · Obesity
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Banner Health Center, Phoenix, Arizona, United States
Indiana University, Indianapolis, Indiana, United States
Mayo Clinic, Rochester, Minnesota, United States
Cleveland Clinic, Cleveland, Ohio, United States
Hospital Alemão Oswaldo Cruz, São Paulo, Brazil
McGill University, Montreal, Canada
Turku University Hospital, Turku, Finland
Sri Aurobindo Institute of Medical Sciences, Indore, India
The Digestive Health Institute, Mumbai, India
University College Dublin, Dublin, Ireland
Università Cattolica del Sacro Cuore, Milan, Italy
Sapienza Università di Roma, Roma, Italy
Kuwait University, Kuwait City, Kuwait
Instituto Nacional de Ciencias Médicas y Nutrición Salvador, Mexico City, Mexico
Contact: Study coordinator (Mauricio Sierra, MD)Hospital Clínic Barcelona, Barcelona, Spain
Linköping University, Linköping, Sweden
Örebro University, Örebro, Sweden
Clarunis Universitäres, Basel, Switzerland
Hôpitaux universitaires de Genève, Geneva, Switzerland
Nuffield Health Bristol Hospital, Bristol, United Kingdom
King's College Hospital, London, United Kingdom
Queen Mary University, London, United Kingdom
Study leads
Ali Aminian, MD
Principal Investigator
The Cleveland Clinic